Taha Ibrahim, Foroni Selena, Valli Roberto, Frattini Annalisa, Roccia Pamela, Porta Giovanni, Zecca Marco, Bergami Elena, Cipolli Marco, Pasquali Francesco, Danesino Cesare, Scotti Claudia, Minelli Antonella
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Front Genet. 2022 Aug 12;13:896749. doi: 10.3389/fgene.2022.896749. eCollection 2022.
Shwachman-Diamond syndrome (SDS) is a rare autosomal recessive ribosomopathy mainly characterized by exocrine pancreatic insufficiency, skeletal alterations, neutropenia, and a relevant risk of hematological transformation. At least 90% of SDS patients have pathogenic variants in the first gene associated with the disease with very low allelic heterogeneity; three variants, derived from events of genetic conversion between and its pseudogene, , provided the alleles observed in about 62% of SDS patients. We performed a reanalysis of the available WES files of a group of SDS patients with biallelic pathogenic variants, studying the results by next bioinformatic and protein structural analysis. Parallelly, careful clinical attention was given to the patient focused in this study. We found and confirmed in one SDS patient a germline heterozygous missense variant (c.100T>C; p.Phe34Leu) in the EIF6 gene. This variant, inherited from his mother, has a very low frequency, and it is predicted as pathogenic, according to several prediction tools. The protein structural analysis also envisages the variant could reduce the binding to the nascent 60S ribosomal. This study focused on the hypothesis that the germline variant mimics the effect of somatic deletions of chromosome 20, always including the locus of this gene, and similarly may rescue the ribosomal stress and ribosomal dysfunction due to mutations. It is likely that this rescue may contribute to the stable and not severe hematological status of the proband, but a definite answer on the role of this variant can be obtained only by adding a functional layer of evidence. In the future, these results are likely to be useful for selected cases in personalized medicine and therapy.
施瓦赫曼-戴蒙德综合征(SDS)是一种罕见的常染色体隐性核糖体病,主要特征为外分泌胰腺功能不全、骨骼改变、中性粒细胞减少以及血液学转化的相关风险。至少90%的SDS患者在与该疾病相关的首个基因中存在致病变异,且等位基因异质性极低;三个源自该基因与其假基因之间基因转换事件的变异,提供了约62%的SDS患者中观察到的等位基因。我们对一组具有双等位基因致病变异的SDS患者的可用全外显子测序(WES)文件进行了重新分析,通过后续的生物信息学和蛋白质结构分析来研究结果。同时,对本研究关注的患者给予了仔细的临床关注。我们在一名SDS患者中发现并确认了EIF6基因中的一个种系杂合错义变异(c.100T>C;p.Phe34Leu)。这个从他母亲那里遗传来的变异频率极低,根据几种预测工具预测其具有致病性。蛋白质结构分析还设想该变异可能会减少与新生60S核糖体的结合。本研究聚焦于这样一个假设,即种系变异模拟了20号染色体体细胞缺失的效应,该缺失总是包括这个基因的位点,并且类似地可能挽救由于该基因突变导致的核糖体应激和核糖体功能障碍。这种挽救可能有助于先证者稳定且不严重的血液学状态,但只有通过增加功能层面的证据才能获得关于这个变异作用的确切答案。未来,这些结果可能对个性化医学和治疗中的特定病例有用。